1.72

4.97% -0.09

After Hours: 1.72

Proqr Therapeutics N V (PRQR)

Overview News Price History Option Chain Discussions Forecast

Proqr Therapeutics N V stock is traded at $1.72, with a volume of 764.13K. It is down -4.97% in the last 24 hours and up +14.67% over the past month. ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.

Previous Close:

$1.81

Open:

$1.84

24h Volume:

764.13K

Relative Volume:

0.85

Market Cap:

$237.51M

Revenue:

$15.53M

Net Income/Loss:

$-52.71M

P/E Ratio:

-3.4229

EPS:

-0.5025

Net Cash Flow:

$-59.00M

1W Performance:

-6.01%

1M Performance:

+14.67%

6M Performance:

-17.31%

1Y Performance:

-21.10%

1-Day Range:

$1.72

$1.87

1-Week Range:

$1.69

$1.945

52-Week Range:

$1.33

$3.10

Proqr Therapeutics N V Stock (PRQR) Company Profile

Name

Proqr Therapeutics N V

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

Address

Employee

187

Twitter

@proqr

Next Earnings Date

2026-08-06

Latest SEC Filings

PRQR's Discussions on Twitter

Compare PRQR vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRQR Proqr Therapeutics N V	1.72	256.84M	15.53M	-52.71M	-59.00M	-0.5025
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Resumed	Oppenheimer	Outperform
Apr-29-25	Resumed	Cantor Fitzgerald	Overweight
Apr-29-25	Initiated	Evercore ISI	Outperform
Mar-10-25	Upgrade	Citigroup	Neutral → Buy
Jan-10-25	Initiated	Oppenheimer	Outperform
Oct-29-24	Upgrade	Raymond James	Outperform → Strong Buy
Nov-08-23	Upgrade	Chardan Capital Markets	Neutral → Buy
Mar-30-23	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Dec-22-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-14-22	Downgrade	Citigroup	Buy → Neutral
Feb-11-22	Downgrade	Raymond James	Strong Buy → Mkt Perform
Feb-11-22	Downgrade	Stifel	Buy → Hold
Feb-01-22	Initiated	Raymond James	Strong Buy
May-03-21	Initiated	Stifel	Buy
Mar-25-21	Reiterated	Citigroup	Buy
Nov-03-20	Resumed	Cantor Fitzgerald	Overweight
Mar-12-19	Reiterated	Chardan Capital Markets	Buy
Dec-19-18	Initiated	RBC Capital Mkts	Outperform
Nov-15-18	Initiated	Citigroup	Buy
Sep-19-18	Initiated	Evercore ISI	Outperform
Sep-26-17	Reiterated	JMP Securities	Mkt Outperform
Jun-20-16	Initiated	Chardan Capital Markets	Neutral
Oct-15-14	Initiated	Deutsche Bank	Buy
Oct-13-14	Initiated	H.C. Wainwright	Buy

View All

Proqr Therapeutics N V Stock (PRQR) Latest News

Jul 01, 2026

PRQRProQR Therapeutics N.V Options - Finviz

Jul 01, 2026

Jun 30, 2026

Bart Filius Acquires 150,000 Shares of ProQR Therapeutics NV - GuruFocus

Jun 30, 2026

Form 13D/A ProQR Therapeutics N.V. For: 30 June By Investing.com - Investing.com South Africa

Jun 30, 2026

Van Herk group reports 10.9% ProQR (PRQR) ownership after share issuances - Stock Titan

Jun 30, 2026

ProQR (PRQR) director receives 14,595-share option grant at $1.42 strike - Stock Titan

Jun 30, 2026

Director Bart Filius buys 150,000 ProQR (PRQR) Ordinary Shares in open market - Stock Titan

Jun 30, 2026

Jun 29, 2026

0PQ Forecast — Price Target — Prediction for 2027 - TradingView

Jun 29, 2026

PRQR Maintained by Evercore ISI Group -- Price Target Raised to $6.00 - GuruFocus

Jun 29, 2026

Jun 27, 2026

Small-cap ProQR Therapeutics secures funding from Eli Lilly on early trial success - MSN

Jun 27, 2026

ProQR prices $50M stock offering; secures $9.2M investment from Eli Lilly - MSN

Jun 27, 2026

Jun 26, 2026

ProQR Therapeutics (NASDAQ: PRQR) raises capital; Lilly to purchase 5.1M shares - Stock Titan

Jun 26, 2026

PRQR Maintains Buy Rating by Jones Trading -- Price Target Lowered to $10.00 - GuruFocus

Jun 26, 2026

Chardan Research Adjusts ProQR Therapeutics Price Target to $3 From $4, Maintains Buy Rating - marketscreener.com

Jun 26, 2026

Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success - Sahm

Jun 26, 2026

ProQR Raises $59 Million in Equity Offering and Eli Lilly Private Placement - TipRanks

Jun 26, 2026

ProQR (PRQR) prices share offering and Eli Lilly private placement - Stock Titan

Jun 26, 2026

Price to book forward of ProQR Therapeutics N.V. – NASDAQ:PRQR - TradingView

Jun 26, 2026

Price to sales forward of ProQR Therapeutics N.V. – LS:A12B97 - TradingView

Jun 26, 2026